Impact of Patisiran on Health Status and Quality of Life in Patients with Transthyretin Cardiac Amyloidosis

Zubair Shah[1], Laura Obici[2], Parag Kale[3], Sumeet S. Mitter[4], Per Eldhagen[5], Toru Hashimoto[6], Edileide de Barros-Correia[7], Matthew T. White[8], Shaun Bender[8], Patrick Y. Jay[8], Kelley Capocelli[8], Mazen Hanna[9]

[1]University of Kansas Medical Center, Kansas City, KS, USA; [2]Amyloidosis Research & Treatment Center, Fondazione IRCCS Policlinico San Matteo di Pavia, Pavia, Italy; [3]Center for Advanced Heart and Lung Disease, Baylor University Medical Center, Dallas, TX, USA; [4]Mount Sinai Hospital, New York, NY, USA; [5]Karolinska University Hospital Solna, Stockholm, Sweden; [6]Kyushu University Hospital, Fukuoka, Japan; [7]Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil; [8]Alnylam Pharmaceuticals, Cambridge, MA, USA; [9]The Cleveland Clinic Foundation, Cleveland, OH, USA

Conclusions

- **In APOLLO-B, patients with transthyretin-mediated (ATTR) cardiac amyloidosis showed improvements in health status and quality of life in Kansas City Cardiomyopathy Questionnaire (KCCQ) Overall Score and across all four of its domains with patisiran compared with placebo at Month 12**
- **Greater percentages of patisiran- versus placebo-treated patients had KCCQ-Overall Summary (KCCQ-OS) improvements of ≥+5 (p<0.05), ≥+10, and ≥+20 points at Month 12, and a smaller percentage had a decline of ≤−5, ≤−10, and ≤−20 points**
- **Treatment effects favoring patisiran versus placebo were observed across 19 of 20 questions that assess the impact of heart failure on symptoms, physical and social limitations, and quality of life, with the largest effects being observed on enjoyment of life, severity of shortness of breath and fatigue, and activities requiring greater exertion**

Background and Rationale

ATTR Amyloidosis

- A progressive and fatal disease caused by accumulation of transthyretin (TTR) amyloid fibrils in multiple organs and tissues[1–4]
- Disease progression has a major impact on patients' functional capacity, health status, and quality of life[5–7]

Patisiran

- An intravenously administered RNA interference (RNAi) therapeutic approved for the treatment of hereditary ATTR (ATTRv; v for variant) amyloidosis with polyneuropathy in the US and EU[8,9]
- Data in patients with ATTR amyloidosis suggest the potential for patisiran to improve cardiac manifestations and preserve functional capacity, health status, and quality of life[10–12]

Objective

- To further characterize the beneficial impact of patisiran on health status and quality of life in patients with ATTR cardiac amyloidosis in the APOLLO-B study (NCT03997383)

Methods

Patisiran Phase 3 APOLLO-B Study

- APOLLO-B was a Phase 3, randomized, double-blind, placebo-controlled study of patisiran versus placebo in patients with ATTR cardiac amyloidosis (**Figure 1**)
- This post hoc analysis evaluated change from baseline to Month 12 in scores for KCCQ-OS, KCCQ Clinical Summary, and KCCQ domains and responses to individual questions

Figure 1. APOLLO-B Study Design



[a]Where tafamidis is available as local standard of care; receiving tafamidis treatment ≥6 months with disease progression in opinion of investigator. [b]To reduce likelihood of infusion-related reactions, patients receive following premedications or equivalent at least 60 minutes before each study drug infusion: dexamethasone; oral acetaminophen; H (histamine) 1 and H2 blockers. [c]Composite all-cause mortality, frequency of cardiovascular (CV) events, and change from baseline in 6MWT; composite all-cause mortality, frequency of all-cause hospitalizations, and urgent HF visits in patients not on tafamidis at baseline; composite all-cause mortality, frequency of all-cause hospitalizations and urgent HF visits in overall population.

Results

Baseline Characteristics

- A total of 359 patients received study drug in APOLLO-B (patisiran, n=181; placebo, n=178)
- Baseline demographics and disease characteristics were similar across the treatment groups (**Table 1**)
  - The majority of patients were male, had ATTRwt cardiac amyloidosis, and were in NYHA Class II
  - Overall, 25% of patients were receiving tafamidis at baseline

Table 1. Baseline Demographics and Disease Characteristics

Characteristic	Patisiran (N=181)	Placebo (N=178)
Age, years, median (range)	76 (47–85)	76 (41–85)
Male sex, n (%)	161 (89.0)	160 (89.9)
Race, n (%)		
White	138 (76.2)	140 (78.7)
Asian	23 (12.7)	15 (8.4)
Black or African American	16 (8.8)	15 (8.4)
ATTRwt cardiac amyloidosis, n (%)	144 (79.6)	144 (80.9)
Time since diagnosis of ATTR amyloidosis, median (range), years	0.8 (0–6)	0.4 (0–10)
Baseline tafamidis use, n (%)	46 (25.4)	45 (25.3)
NYHA Class, n (%)		
Class I	10 (5.5)	15 (8.4)
Class II	156 (86.2)	150 (84.2)
Class III	15 (8.3)	13 (7.3)
ATTR amyloidosis stage[a], n (%)		
Stage 1	124 (68.5)	120 (67.4)
Stage 2	46 (25.4)	45 (25.3)
Stage 3	11 (6.1)	13 (7.3)
Polyneuropathy disability (PND) score, n (%)		
0: no impairment	96 (53.0)	109 (61.2)
I: preserved walking, with sensory disturbances	63 (34.8)	55 (30.9)
II: impaired walking without need for a stick or crutches	22 (12.2)	14 (7.9)
6MWT, m, median (interquartile range [IQR])	358.0 (295.0–420.0)	367.7 (300.0–444.3)
KCCQ-OS, points, mean (SD)	69.8 (21.2)	70.3 (20.7)
NT-proBNP level, ng/L, median (IQR)	2008 (1135–2921)	1813 (952–3079)
High-sensitivity troponin I level, ng/L, median (IQR)	64.0 (38.6–92.0)[b]	60.2 (38.2–103.1)[c]
Estimated glomerular filtration rate (eGFR), mL/min/1.73 m², median (IQR)	71.0 (58.0–83.0)	67.0 (51.0–84.0)

[a]Patients are classified into categories using the parameters NT-proBNP and eGFR. Patients are categorized as follows: stage 1 (lower risk): NT-proBNP ≤3000 ng/L and eGFR ≥45 mL/min/1.73 m²; stage 2 (intermediate risk): all other patients not meeting criteria for stage 1 or 3; stage 3 (higher risk): NT-proBNP >3000 ng/L and eGFR <45 mL/min/1.73 m². [b]n=174. [c]n=172.

Changes in KCCQ-OS Score and its Individual Components

- Patisiran demonstrated significant clinical benefit in health status and quality of life (KCCQ-OS) compared with placebo at Month 12 (least squares [LS] mean difference 3.7 [95% confidence interval (CI) 0.2, 7.2]; **Figure 2**)
  - The treatment benefit with patisiran was observed across all four domains of the KCCQ and the KCCQ Clinical Summary Score
- More patisiran-treated patients achieved improvements of ≥+5, ≥+10, and ≥+20 points in KCCQ-OS score at Month 12 compared with placebo (**Figure 3**)
  - Significantly more patisiran- than placebo-treated patients improved by ≥+5 points (p<0.05)
- More placebo-treated patients showed a deterioration of ≤−5, ≤−10, and ≤−20 points compared with patisiran

Figure 2. LS Mean Difference between Patisiran and Placebo in Change from Baseline in KCCQ-OS, the Four Domains of the KCCQ, and KCCQ Clinical Summary Score at Month 12



Figure 3. Proportion of Patients by Threshold of Change from Baseline to Month 12 in KCCQ-OS Score



*p-values were calculated using the Cochran–Mantel–Haenszel test stratified by baseline tafamidis use.

Treatment Effects across Individual Questions in the KCCQ-OS

- Treatment effects favoring patisiran were demonstrated across 19 of the 20 questions in the four KCCQ-OS components (**Figure 4**)
- Among the largest treatment effects observed were those related to walking and demanding physical activities, such as hurrying or jogging and climbing stairs, as well as shortness of breath and fatigue that limit exertion
- The greatest treatment effect was observed in the question related to the impact of HF on the patient's enjoyment of life
- An effect on orthopnea suggested a benefit among patients with more severe HF
- The only question where no treatment benefit was observed was for "dressing yourself," which requires minimal exertion and was not a limitation for most patients in either treatment arm at baseline or Month 12
- Patients in the placebo group showed higher rates of worsening for almost all KCCQ questions compared with patisiran (data not shown)

Figure 4. Mean Treatment Difference in Change from Baseline to Month 12 in Individual KCCQ-OS Questions



We thank the patients, their families, investigators, study staff, and collaborators for their participation in the APOLLO-B study. **Acknowledgments:** Medical writing assistance was provided by Olympia Gianfrancesco, PhD, of Adelphi Communications Ltd, UK, and funded by Alnylam Pharmaceuticals in accordance with Good Publication Practice Guidelines. **Funding:** This study was funded by Alnylam Pharmaceuticals.

Disclosures: Z.S. reports advisory board membership and independent contractor work for Alnylam Pharmaceuticals; L.O. reports consulting fees from Alnylam Pharmaceuticals, AstraZeneca, BridgeBio, Ionis, Novo Nordisk, Pfizer, and SOBI, and payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Alnylam Pharmaceuticals, Pfizer, and SOBI; P.K. reports consulting fees from Alnylam Pharmaceuticals; S.S.M. reports honoraria for lectures from Alnylam Pharmaceuticals, Scripps Health, and Stamford Hospital, support for attending meetings from Alnylam Pharmaceuticals and the Amyloid Research Consortium FDA Meetings (2022, 2023), and participation in advisory boards for Alnylam Pharmaceuticals, BridgeBio, and Pfizer; P.E. reports grants or contracts from FAMY Norbotten and Pfizer, consulting fees and payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Alnylam Pharmaceuticals and Pfizer, and advisory board membership for Alnylam Pharmaceuticals, Bristol Myers Squibb, and Pfizer; T.H. has nothing to disclose; E.deB.-C. reports grants or contracts from Bristol Myers Squibb, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Alnylam Pharmaceuticals, Bristol Myers Squibb, Pfizer, Pint-Pharma, and Sanofi Genzyme, support for attending meetings from Alnylam Pharmaceuticals, Bristol Myers Squibb, and Pfizer, and data safety monitoring or advisory board membership for Alnylam Pharmaceuticals and Pfizer; M.T.W., S.B., P.Y.J., and K.C. are employed by Alnylam Pharmaceuticals and report ownership of Alnylam Pharmaceuticals shares; M.H. reports consulting fees from Alexion, Alnylam Pharmaceuticals, Eidos, Ionis, and Pfizer, and participation in data safety monitoring or advisory boards for Ionis (CardioTTRansform trial). **Abbreviations:** 6MWT, 6-minute walk test; ATTR, transthyretin-mediated; ATTRv, hereditary transthyretin (v for variant); ATTRwt, wild-type transthyretin; CI, confidence interval; CV, cardiovascular; eGFR, estimated glomerular filtration rate; H, histamine; HF, heart failure; IQR, interquartile range; IV, intravenous; KCCQ, Kansas City Cardiomyopathy Questionnaire; KCCQ-OS, Kansas City Cardiomyopathy Questionnaire-Overall Summary; LS, least squares; NT-proBNP, *N*-terminal prohormone of B-type natriuretic peptide; NYHA, New York Heart Association; PND, polyneuropathy disability; Q, question; Q3W, once every 3 weeks; RNAi, RNA interference; SD, standard deviation; TTR, transthyretin.
References: 1. Hawkins et al. *Ann Med* 2015;47:625–38; 2. Ruberg et al. *J Am Coll Cardiol* 2019;73:2872–92; 3. Maurer et al. *J Am Coll Cardiol* 2016;68:161–72; 4. Sipe et al. *Amyloid* 2014;21:221–4; 5. Castano et al. *Heart Fail Rev* 2015;20:163–78; 6. Ruberg et al. *Am Heart J* 2012;164:222–8.e1; 7. Lane et al. *Circulation* 2019;140:16–26; 8. Food and Drug Administration 2018. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210922s000lbl.pdf (accessed June 2023); 9. European Medicines Agency 2018. Available from: https://www.ema.europa.eu/en/documents/product-information/onpattro-epar-product-information_en.pdf (accessed June 2023); 10. Adams et al. *N Engl J Med* 2018;379:11–21; 11. Solomon et al. *Circulation* 2019;139:431–43; 12. Maurer et al. *Heart Failure Society of America (HFSA) 2022 Annual Meeting* (Poster 341).
Presented at: Heart Failure Society of America (HFSA) Annual Scientific Meeting, Huntington Convention Center of Cleveland, Cleveland, OH, October 6–9, 2023.